<SEC-DOCUMENT>0001023024-25-000072.txt : 20250723
<SEC-HEADER>0001023024-25-000072.hdr.sgml : 20250723
<ACCEPTANCE-DATETIME>20250723065300
ACCESSION NUMBER:		0001023024-25-000072
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250723
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250723
DATE AS OF CHANGE:		20250723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANI PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001023024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				582301143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31812
		FILM NUMBER:		251141586

	BUSINESS ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623
		BUSINESS PHONE:		2186343500

	MAIL ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOSANTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19991228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEN ABRAHAM TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ani-20250723.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7d3d46ce-2533-4c4c-8b47-78ec92dd4499,g:669d1028-3569-4e29-b988-af2165055840,d:90b9594fe9ee4aada1cb2108d4c06945-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ani-20250723</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001023024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ani-20250723.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-23</xbrli:startDate><xbrli:endDate>2025-07-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90b9594fe9ee4aada1cb2108d4c06945_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of Earliest Event Reported): </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 23, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ANI PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-31812</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">58-2301143</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">210 Main Street West</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Baudette</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Minnesota</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">56623</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">218</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">634-3500</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">ANIP</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Growth Company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#168;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i90b9594fe9ee4aada1cb2108d4c06945_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2025, ANI Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is announcing select preliminary unaudited financial results for the second quarter ended June 30, 2025. The Company expects combined ILUVIEN</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#174; </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and YUTIQ</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> net revenues of $22.3 million for the three months ended June 30, 2025.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This information is preliminary and unaudited and reflects the Company&#8217;s estimated financial results for the second quarter 2025. The Company&#8217;s actual financial results for the second quarter ended June 30, 2025, have not yet been finalized by management or reviewed by the Company&#8217;s independent auditors, EisnerAmper LLP. The foregoing financial results are not a comprehensive statement of all financial results for the second quarter ended June 30, 2025. Subsequent information or events may lead to material differences between the foregoing preliminary unaudited financial results and those reported in the Company&#8217;s subsequent filings with the Securities and Exchange Commission. Accordingly, investors should not place undue reliance on these preliminary unaudited financial results.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Regulation FD Disclosure. </span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Other Events.</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on July 23, 2025, the Company issued a press release and held a conference call announcing the results of the NEW DAY Study. The full text of the Company&#8217;s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div id="i90b9594fe9ee4aada1cb2108d4c06945_10"></div><div style="-sec-extract:summary;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20250723xexx991.htm">Press Release, dated July 23, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded with the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">The information in this Current Report on Form 8-K furnished pursuant to Item 2.02 and Item 7.01 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i90b9594fe9ee4aada1cb2108d4c06945_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: July 23, 2025</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ANI PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Nikhil Lalwani</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Nikhil Lalwani</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>anip-20250723xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1b56a9813f594b09b763c5062a125930_37"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:12pt"><img alt="a1a.jpg" src="a1a.jpg" style="height:102px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">FOR IMMEDIATE RELEASE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN&#174; for Use in Patients with Diabetic Macular Edema (DME) </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Study Enrolled Treatment-Na&#239;ve, or Almost Na&#239;ve, Patients with DME</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Conference call scheduled for today at 8&#58;30 am ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> - ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq&#58; ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN&#174; (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macular edema (DME). The results were presented in a paper-on-demand presentation by Michael A. Singer, M.D., Clinical Professor of Ophthalmology at University of Texas Health Science Center and Director of Clinical Research at Medical Center Ophthalmology Associates in Texas, for the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The primary endpoint of the trial was the mean total number of supplemental aflibercept injections needed for the treatment of DME in the ILUVIEN arm compared to the aflibercept arm over the 18-month study period in the intent-to-treat (ITT) population. Patients were randomized to an induction phase to receive either a single ILUVIEN injection or a series of 5 monthly injections of aflibercept, followed by supplemental aflibercept injections as needed. Treatment with ILUVIEN (n&#61;154) demonstrated a numerical reduction in the mean number of supplemental aflibercept injections compared to the aflibercept arm (n&#61;152) but did not reach the threshold for statistical significance (2.4 vs. 2.5&#59; p&#61;0.756), and therefore the primary endpoint was not met. The secondary endpoint of mean time from last treatment injection to first supplemental aflibercept injection was met with a mean time of 185.4 days in the ILUVIEN arm (n&#61;154), compared to 132.8 days in the aflibercept arm (n&#61;152) (p&#60;0.001). Thirty-three percent of patients in the ILUVIEN arm did not require a supplemental injection during the study compared to thirty percent in the aflibercept arm (p&#61;0.678).</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A post-hoc analysis was conducted on a subset of randomized patients without major protocol deviations&#8212;such as being enrolled or randomized despite not meeting eligibility criteria, receiving incorrect treatment, or being administered prohibited concomitant medications or therapies. In this Post-Hoc Patient (PP) Population, the ILUVIEN arm (n&#61;128) demonstrated a statistically significant difference in the mean number of supplemental aflibercept injections compared to the aflibercept arm (n&#61;134), with 1.8 vs. 2.5 injections, respectively (p&#61;0.029).  Patients randomized to the ILUVIEN arm therefore received a single ILUVIEN injection and a mean of 1.8 supplemental injections, for a total of 2.8 injections, compared to patients in the aflibercept arm, who received 5 initial aflibercept injections and a mean of 2.5 supplemental injections, for a total of 7.5 injections.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Research suggests that DME is a multifactorial disease driven not only by increased production of VEGF, but also chronic inflammation,&#8221; said Dr. Singer. &#8220;The NEW DAY study provides clinically meaningful data on ILUVIEN&#8217;s potential impact on treatment burden, including a statistically significant difference in time to first supplemental injection of aflibercept in the ILUVIEN arm compared to the aflibercept arm. This potential reduction in treatment burden can be critical for our patients with diabetic macular edema as their disease is multifactorial, necessitating multiple visits to medical specialists.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In addition, secondary endpoints that assessed visual acuity and anatomic changes in the ITT population demonstrated non-inferiority between the ILUVIEN arm and the aflibercept arm. The mean change from baseline in best corrected visual acuity (BCVA) score over 18 months in patients who did not meet the prespecified non-inferiority margin of 4 ETDRS (Early Treatment Diabetic Retinopathy Study) letters was 1.8 in the ILUVIEN arm (n&#61;154) versus 5.5 in the aflibercept arm (n&#61;152) (p&#61;0.080 at month 18). The mean change from baseline in central subfield thickness (CST) over 18 months in the ILUVIEN arm was -118.8 compared to -113.6 in the aflibercept arm (p&#61;0.709 at month 18). Additional secondary endpoints will be further evaluated.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;ILUVIEN is already an established treatment option for diabetic macular edema and the results of the NEW DAY trial further highlight its potential as an important option for patients impacted by this disease,&#8221; stated Nikhil Lalwani, President and Chief Executive Officer of ANI. &#8220;We believe these data have the potential to support earlier usage of ILUVIEN as part of its role in reducing treatment burden in DME. We are pleased to share the results at the ASRS meeting and look forward to presenting additional data in the future to further inform clinical decision-making.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For safety, ILUVIEN was well tolerated in the trial, with a safety profile that is consistent with data from prior ILUVIEN clinical trials and real-world use. In the ITT patient population, 41 percent of patients in the ILUVIEN arm experienced treatment-related treatment-emergent adverse events (mainly associated with cataract&#47;subcapsular cataract (n&#61;50) and increase in intraocular pressure (IOP) (n&#61;24)), compared to 3 percent in the aflibercept arm.  Serious treatment-related treatment-emergent adverse events were not seen in either arm. Sixteen percent of patients in the ILUVIEN arm experienced an increase in IOP compared to 3 percent in the aflibercept arm. In the ILUVIEN arm, 11 percent of patients experienced an increase in IOP of &#8805;25 mmHg compared to 3 percent in the aflibercept arm. In the ILUVIEN arm, 4.5 percent of patients required any laser or incisional IOP-lowering intervention during the study compared to 1.3 percent in the aflibercept arm.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About The NEW DAY Clinical Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">NEW DAY is a prospective, multicenter, masked, randomized, active-controlled trial that enrolled 306 eyes of treatment-na&#239;ve, or almost na&#239;ve, DME patients at approximately 42 sites around the U.S. To be enrolled in the study, patients had to be &#8805;18 years old with a diagnosis of Type 1 or Type 2 diabetes with center-involving DME confirmed by SD-OCT and CST of &#8805; 350&#181;m and best corrected visual acuity (BCVA) of &#8805;35 ETDRS Letters and &#8804;80 ETDRS letters in the study eye at the screening visit. Patients were excluded from the study if, among other things, they had received the following in the study eye&#58; intravitreal or periocular steroids, intravitreal injection of aflibercept, brolucizumab, or conbercept &#8804;12 months prior to screening visit&#59; &#62; 1 intravitreal injection of ranibizumab or bevacizumab in the last 12 months&#59; or had received ranibizumab or bevacizumab &#8804; 6 weeks prior to the screening visit. Patients were also screened with a steroid challenge of difluprednate QID for 2 weeks. Patients who were determined to have an IOP &#8805;25 mmHg or an increase &#8805;8 mmHg from the screening visit were excluded. Patients were randomized to either an ILUVIEN arm or an aflibercept arm. Patients in the ILUVIEN arm received an ILUVIEN intravitreal implant while patients in the aflibercept arm received five injections of anti-VEGF therapy (intravitreal aflibercept 2 mg) at four-week intervals for the first 16 weeks of the trial during an induction period. After the 16-week induction period, patients in both arms were evaluated every four weeks during a 13-month maintenance period and received supplemental aflibercept injections only as needed. The criteria for supplemental treatment was set by identical protocol in both arms. Patients in the ILUVIEN arm were also permitted to receive supplemental aflibercept injections during the induction period if needed by protocol criteria following the injection of ILUVIEN. During the maintenance period, patients in the aflibercept arm only received supplemental aflibercept injections if needed per protocol definition. The recommended dosing in the prescribing information for aflibercept is an injection once every 8 weeks following an injection every 4 weeks for the first 5 injections. The primary endpoint of the study was the mean number of supplemental aflibercept injections needed for the treatment of DME in the study eye during the study in the ITT population.     </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About Diabetic Macular Edema</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Diabetic macular edema (DME) occurs when blood vessels leak into a part of the retina called the macula, causing swelling that can lead to blurry vision and vision loss. Over time, about 7% of people with diabetes will develop DME, and approximately 4% will develop clinically significant macular edema, which causes blurred vision in the early stage and may cause cumulative damage over the long term. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">INDICATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IMPORTANT SAFETY INFORMATION</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONTRAINDICATIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WARNINGS AND PRECAUTIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Intravitreal Injection-related Effects&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Patients should be monitored following the intravitreal injection. Patients may experience temporary blurred vision after injection of the implant. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Intraocular Pressure (IOP) Increase&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Cataracts&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> The use of corticosteroids may result in posterior subcapsular cataract formation. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Delayed Corneal Wound Healing&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Corneal and Scleral Melting&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Bacterial Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Viral Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution&#59; frequent slit lamp microscopy is recommended. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Fungal Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Risk of Implant Migration&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADVERSE REACTIONS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Diabetic Macular Edema</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of ILUVIEN for diabetic macular edema include&#58; cataract (82%), myodesopsia (21%), eye pain (15%), conjunctival hemorrhage (13%), posterior capsule opacification (9%), eye irritation (8%), vitreous detachment (7%), conjunctivitis (4%), corneal oedema (4%), foreign body sensation in eyes (3%), eye pruritus (3%), ocular hyperaemia (3%), optic atrophy (2%), ocular discomfort (2%), photophobia (2%), retinal exudates (2%), anterior chamber cell (2%), and eye discharge (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients include&#58; anemia (11%), headache (9%), renal failure (9%), and pneumonia (7%)  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Increased Intraocular Pressure&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 34% of ILUVIEN patients versus 10% of sham patients. IOP elevation greater than or equal to 30 mm Hg was seen in 20% of ILUVIEN patients versus 4% of sham patients. 38% of the patients who received ILUVIEN were subsequently treated with IOP-lowering medications during the study versus 14% of sham patients. 5% of the patients who received ILUVIEN needed surgical intervention for elevated IOP versus 1% of sham patients   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Cataracts and Cataract Surgery&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> The incidence of cataract development in patients who had a phakic study eye was higher in the ILUVIEN group (82%) compared with sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the ILUVIEN group and 19 months in the sham group. Among these patients, 80% of ILUVIEN subjects versus 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 months (median month 15 for both ILUVIEN group and for sham) of the studies.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Please see full Prescribing Information.   </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Conference Call</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company&#8217;s management will host a conference call today to discuss the NEW DAY clinical trial.   </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.089%"><tr><td style="width:1.0%"></td><td style="width:42.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wednesday, July 23, 2025</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Time </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#58;30 am ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Toll Free (U.S.)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800-267-6316</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This conference call will also be webcast and can be accessed from the &#8220;Investors&#8221; section of ANI&#8217;s website at www.anipharmaceuticals.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A replay of the conference call will also be available within two hours of the call&#8217;s completion and will remain accessible for two weeks by dialing 800-839-2485 and entering access code 5029808.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About ANI Pharmaceuticals, Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ANI Pharmaceuticals, Inc. (Nasdaq&#58; ANIP) is a diversified biopharmaceutical company committed to its mission of &#8220;Serving Patients, Improving Lives&#34; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology&#59; its Generics business, which leverages R&#38;D expertise, operational excellence, and U.S.-based manufacturing&#59; and its Brands business. For more information, visit www.anipharmaceuticals.com. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company&#8217;s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;shall,&#8221; &#8220;would&#8221; other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.   </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements&#58; the ability of our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability&#59; our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all&#59; the limitation of our cash flow as a result of the indebtedness and liabilities incurred from the  acquisition of Alimera&#59; the risks that our acquisitions and investments, including the  acquisition of Alimera, could disrupt our business and harm our financial position and operating results&#59; delays and disruptions in production of our approved products, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials&#59; delays and disruptions in production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, ILUVIEN and YUTIQ&#59; delays or failure in obtaining and maintaining approvals by the FDA of the products we sell&#59; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies, and the focus of the current U.S. presidential administration, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions&#59; risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason, including increased costs due to tariffs&#59;&#59; the ability of our manufacturing partners to meet our product demands and timelines&#59; the impact of changes or fluctuations in exchange rates&#59; our ability to develop, license or acquire, and commercialize new products&#59; our obligations in agreements under which we license, develop or commercialize rights to products or technology from third parties and our ability to maintain such licenses&#59; the level of competition we face and the legal, regulatory and&#47;or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products&#59; our ability to protect our intellectual property rights&#59; the impact of legislative or regulatory reform on the pricing for pharmaceutical products&#59; the impact of any litigation to which we are, or may become, a party&#59; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries&#59; our ability to maintain the services of our key executives and other personnel&#59; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies. More detailed information on these and additional factors that could affect the Company&#8217;s actual results are described in the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company&#8217;s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Investor Relations&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Lisa M. Wilson, In-Site Communications, Inc. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">T&#58; 212-452-2793 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E&#58; lwilson&#64;insitecony.com  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ani-20250723.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7d3d46ce-2533-4c4c-8b47-78ec92dd4499,g:669d1028-3569-4e29-b988-af2165055840-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ani="http://ani.com/20250723" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ani.com/20250723">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20250723_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20250723_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://ani.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ani-20250723_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7d3d46ce-2533-4c4c-8b47-78ec92dd4499,g:669d1028-3569-4e29-b988-af2165055840-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_48d443f8-4660-478f-bbed-81119339ae25_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_89816561-0556-4bde-a837-2e87b45ac6ae_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0a41b3d6-8314-4e25-bc76-1075568b58c8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ab26e6bf-ee60-4195-abfc-519ee542ca1e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5a90c582-ec72-43a3-be73-fae325a17261_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_949ad608-7b62-43e9-8a61-bffa5d284171_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_72c77135-d92b-48c5-bf68-149e1787ee6d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f428097c-7d7f-4f30-9910-cc281e9dcdc1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b714a83d-4011-4c87-917a-01c7faba0918_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b1ce2887-5353-4bd9-963a-c57284de8560_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a6dafca8-70db-4e76-8ae2-25a61c9a7afa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1c74ad4f-1db3-42d5-93e5-2fb034ca8a3d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_56f82318-dc30-459b-afc8-e255f19580a1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fd8bcd85-5848-45cf-8616-85fbb7c91765_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c067448a-3944-4942-90fb-ce98f76697d2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_76d84ef9-08f6-495b-88b2-8cd76cf3a0e4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bb57982f-d268-4cf8-9479-af33ddbfb9d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_db861d1c-dfd5-42af-a5de-5385b963ae40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_94a9758b-994c-4a23-8b46-61492d9d4e0d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6b3e6b9c-8f27-4133-88af-384a1da6029d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7cf42a6d-b733-4f6e-9afe-98341f6aa32e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_595a47ec-50d3-4987-9034-31fded26de05_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ani-20250723_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7d3d46ce-2533-4c4c-8b47-78ec92dd4499,g:669d1028-3569-4e29-b988-af2165055840-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ani.com/role/Cover" xlink:type="simple" xlink:href="ani-20250723.xsd#Cover"/>
  <link:presentationLink xlink:role="http://ani.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_154dbe49-ab35-4233-913b-aeb28691f520" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_DocumentType_154dbe49-ab35-4233-913b-aeb28691f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1a90c15a-962d-4b9e-b6b2-e3bf70bfcd70" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_DocumentPeriodEndDate_1a90c15a-962d-4b9e-b6b2-e3bf70bfcd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_451913c2-fcf5-4de5-a19f-510272d4ad89" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityRegistrantName_451913c2-fcf5-4de5-a19f-510272d4ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_aa3dbbf3-027f-40b1-9a0c-7635201a72cf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_aa3dbbf3-027f-40b1-9a0c-7635201a72cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ee61df82-7a7a-4906-8505-870b5944dbd5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityFileNumber_ee61df82-7a7a-4906-8505-870b5944dbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_aa2998de-30eb-4384-8e82-47649c77914f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityTaxIdentificationNumber_aa2998de-30eb-4384-8e82-47649c77914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_818ae489-653c-4c21-9700-cba5100bdaa3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityAddressAddressLine1_818ae489-653c-4c21-9700-cba5100bdaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_94470b7b-9e5a-485a-bca7-8da1ce8f5f84" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityAddressCityOrTown_94470b7b-9e5a-485a-bca7-8da1ce8f5f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e4c2f28f-9863-4949-8a30-237096a4782f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityAddressStateOrProvince_e4c2f28f-9863-4949-8a30-237096a4782f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a7ab8543-2794-4716-a74d-c6470f5e98e0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityAddressPostalZipCode_a7ab8543-2794-4716-a74d-c6470f5e98e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_398586c1-b968-4dab-a798-d2abdfa7c8b6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_CityAreaCode_398586c1-b968-4dab-a798-d2abdfa7c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fdbc7411-2cfe-4b6e-a457-e46d44a0441c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_LocalPhoneNumber_fdbc7411-2cfe-4b6e-a457-e46d44a0441c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7ed30c31-05dc-4574-8fd2-5c9f5d5986a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_Security12bTitle_7ed30c31-05dc-4574-8fd2-5c9f5d5986a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6eecd6a7-421c-45da-916c-f0f923374677" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_TradingSymbol_6eecd6a7-421c-45da-916c-f0f923374677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2f2ed1f9-dfb6-468f-903d-83f728aef9ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_SecurityExchangeName_2f2ed1f9-dfb6-468f-903d-83f728aef9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_770c9874-79d2-400e-9d7a-e49d20cef15e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_WrittenCommunications_770c9874-79d2-400e-9d7a-e49d20cef15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5a8f2583-1ab9-41ac-b0db-bfdbcd7b7840" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_SolicitingMaterial_5a8f2583-1ab9-41ac-b0db-bfdbcd7b7840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_761241b4-291b-4dad-8f69-2003213c7a98" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_PreCommencementTenderOffer_761241b4-291b-4dad-8f69-2003213c7a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_53a8f176-52e0-4696-b137-bb85b77ba210" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_53a8f176-52e0-4696-b137-bb85b77ba210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9da2fd10-3b0f-440b-8cf3-673ccb43afad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityEmergingGrowthCompany_9da2fd10-3b0f-440b-8cf3-673ccb43afad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2c268a10-a976-49eb-95ec-0418fd851217" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_EntityCentralIndexKey_2c268a10-a976-49eb-95ec-0418fd851217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f98fbe4f-ea5a-4100-aa0e-bde28052155b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_289cbe46-3098-4083-ac24-c43a44737d1c" xlink:to="loc_dei_AmendmentFlag_f98fbe4f-ea5a-4100-aa0e-bde28052155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F ,H# 2(  A$! Q$!_\0
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M6:\/R!AC$8Z'\3D_E7F'AO1I->UVUL4^Z[9D/]U!RQ_SW-?1D42Q1K&BA44
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METD>[;YI3'X[?3G-6[_PYK-UXZL_$$+V,:6]B]ML9V8[VR=V-HR 2.,\CTK
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 23,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANI PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2301143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 Main Street West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baudette<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">56623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">634-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANIP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001023024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ani-20250723.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ani.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ani-20250723.htm">ani-20250723.htm</File>
    <File>ani-20250723.xsd</File>
    <File>ani-20250723_lab.xml</File>
    <File>ani-20250723_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ani-20250723.htm": {
   "nsprefix": "ani",
   "nsuri": "http://ani.com/20250723",
   "dts": {
    "inline": {
     "local": [
      "ani-20250723.htm"
     ]
    },
    "schema": {
     "local": [
      "ani-20250723.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ani-20250723_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ani-20250723_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://ani.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20250723.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20250723.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001023024-25-000072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001023024-25-000072-xbrl.zip
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MN8)E'6:!;3,)7X>*U(9#'^P+%/C9IWFU1AYT1?WH"D(G@.BXZB9T)(6/-':
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M$"O7EU31^$*^(S;H,L^;_VF@I@ZH1/^ D)?<DOR]FP:70%+Y(48J[P,B_?T
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M*78&8^H*G[CJ[Z!T(WHR=_V41GF>!]9K1LZ2B:125/ ^.&BD:$!J!NKMS-H
M:PGES#,3A-WT_&HD^*80ASB)?W@#G=LD &4&U\I=[/6X$/JE,2&4N88*=AWZ
MC^579'FI?$.!ZD+='?'>^!$K9MZU,&^NASK;P]WGD\6V2788%\2%*:!DG-DQ
M"^T7(;Q_E3&RK&EPC#V*TBHHOO&Y/1_?94_N(>\0*:EH6UW.VY=UEM8;7<_Z
MC0H.5VKW_V;MK&&WR_/!*U!+ P04    " "=-O=:*'BCA?L)  !]5   %
M &%N:2TR,#(U,#<R,U]L86(N>&ULQ9Q=;]LX%H;O^RNTV9M=8%B+$B6119M!
M-],.BLVT09-B!KM8&/Q,A,I2("M-\N^7E.U$BF59I&SU)G%L^KSG/>'C<R1;
M?OOKPR+S?LARF1;YNQ/XVC_Q9,X+D>;7[TZ^77T$^.37TU>OWOX-@+_^]?7<
M^ZW@=PN95]Y9*6DEA7>?5C=>=2.]/XOR>_J#>A<9K511+@ XK9]V5MP^ENGU
M3>4%?A!MEFT>+=\D(A0HYA($41@"Q!$'F*$$)%AR$@B!$"&_7+^)8R*@'V 0
M1C$!2 8$,((QH"J <>1'$49^'31+\^]OS ]&E]+3]O)E_>>[DYNJNGTSF]W?
MW[]^8&7VNBBO9X'OA[/-ZI/U\H>M]?=AO1H20F;UHT]+EVG70AT6SO[ZX_R2
MW\@%!6F^K&C.C< R?;.L[SPO.*WJJN_-R]NYPOP%-LN N0O  (3P]<-2G)R^
M\KQ5.<HBDU^E\LSO;U\_[90D,[-BELMK\[^]D&5:B,N*EM4Y93+3V=?1JL=;
M^>YDF2YN,[FY[Z:4JCML5I:MJ"9+8K*$L<GR[[O$9B/2/U"^U7:N!TBNMOOY
M4#GVU?3SP=*]TJ\0\O@)-V1&I[S:4!]R,=7>?9(:G?KQ,S[4MB@JFDVP+9YE
M&BEGYHYS?6LM8P+UO)C6.NN7[D:J\J&2N9"K5\M6:"\5[T[TK;F0Z?RRR%*>
M5KHM_J$S*E.:S1'6O2E4&* X]@%*L *,:0\80DC"D% 91//J:4?/90Z^76[$
M:X6^\"<6KJH==)9R6=R5?-77M*3IZ:LL3I\%O8WBV]ES9M;%R(YL,3N:NX*W
MHF:F+1?E2Q,%WV/B>9,OM8O:P5+RU]?%CYE^XLS,/N8&,#?JO;TCW&RK]._+
M38:TY'MJM5XQXX6>-FXKT"J;*HO%$"M5,>2_MBJ7%CSQBE+(4D^/'<FW]LV?
M95IIVLZ*Q>(N3U?CSW*."=837 R!'N)B@)B0@.(P 8'$"4,1Y3&50SGJ5#@R
M2FM-KRTZG*;NJNP':K17.Z8L;5IAU6O%B:SNB)/!U6NHR5?_0GO$S%%%=G%3
MY/+SW8+)<NY3!%DH8H!#B,QQ4P083V( _43CAEF$.1Y*U\O@1P:KEO-J/6\E
M.!RJK3KLYVF,.SN4+(Q98;3+@1-!6\$F@V>7C28W.]?8(W-6_)#E>[:L2LJK
M ?NDM?YXFZ26\?Z[$?K?8;9(9_).^Z,=:;+-T6F@N3.Z%]AOB\V9KJ>#N]_T
M #2G+(AES!20T@S]D$2 ,L5!!(F4$0HXA8.'E4Z%([^F/IV_6XEZ6M4SLL-?
M6;OKLA^;T6[M\+$V:H51KQDGG+HC3H95KZ$F7OT+[3&[**49?J3.T(2],@?C
MY1>E=,N.*/%YA ,@>1( %-(0,)F$0%$9!A&%21##H:SMECDR<%H8\(:RMY+V
M:NWAU/64:3]ZAS%OQY^;;RL(]]MR(K$G[&0X[K?69'+ :GLPW^M0PH3[F-'K
M.4&$BMC'(&&Q85$2@*D^9F=*T4@$&,%D,(NMR$?&[TG+,V+#>6N[WX^8LR<[
MJ@;:L<*H,W4G<MJ1)H.ETT"3C^X%]DA\R*NT>CS3@4J:?=*0/?Q;/LZ3@"<)
M#",@2,  PEP?8:L8 XB(A E.]*0HAJ+1J7!D1%::WEK4JU4]+3L<ENZZ[(=F
MM%L[>*R-6F'4:\8)I^Z(DV'5:ZB)5__"T2/AI^7R3I;-B4>A /LDX2 1B0)(
MA3X@!/J \P!#2007W'4PW!*;>CQ<)7"8*7&[<M:SXJAZC)P8;4HQ9G#<Z?$0
MX^-V\)\U1.ZTV3-*[GZ.:_>\H@^?A(Z<JO79[O7Y699 1'$H /(A!(CC!!"8
M4.!#GBC*J$_@X//4O4K3=%,M[K75K4]A]]=K:'<]0!6<NJQ] 1RZ[1YS([KN
MKL@3=]\]!K>[\+XGN&+[82'+ZS2__KTL[JL;_1)Q2_/'.8-<!EBC&H51:-ZZ
M)8#$(04\2O0AH9 XBGT[:#MUID%V(^VMM+VUN"VPW94:BNMH_TZPVEIW0+77
MV A0N^-.C&FON6U(^Y>[(OHQS39O=M)84,4I!HDO]"&I3&* J0Q $-$8<D(3
MJJ@=E\_!IX'1Z#EVS$8=AE+GYLX)M2'&'/#:=C""J4:PB4':MK%-3\<:5V2^
MRNO4O%&85Y_I0L[UJ(FH0 I P70["T0$2"@C$"CFATCS1$/+,SEM@6G0>=;T
MC*@M/B]J,A0A=Z=.& TUZ8!2MY,1.+T(.#%2W7:VL=JQSAZM2\GO2M/E'OB-
M_L_)>AM%L<)!"#$0//0!B@@#ND-A((,H4I!$V*>#3]ET"1P9K8VDM]&T1*NS
M)OO1&NO4#BU+DW8?G.UQXO;1V:Z TWUXML=.Z^.S?>OLT;HJJ;DRZ_)QP8IL
MK@1F7. (1!AAS117 ,=0CWJ18BSA!";QX ^@MR(?&::UEK<2&PY1V_U^>IP]
MV6$ST(X5+IVI.W'2CC09()T&FF1T+W =Y#[EO"AOB[(^Y7%9T4J>%7=Y53Z>
M%4+.N1\G"&$*0H(00 0%@/B* 2X)5DD<DT0$=G-=K]XT8UXKA5^\.@E=-6^=
MB&<RL9W]^LLX=!0\6'&<)L-1=7$8%P>Y'3$]]L>?>)@<9'9[MASV-/=1$P;L
M*JTR.4]B@9%4!/A8Q9KTB &,60 P%TG,54A]B6S'S$WP8W=%H^$5RH/!/]@_
MO8VZ_8SY5(SA\Z6+1<LF:>G.:;A\:6/48/D4;/*A\J6-KH%R:XUKYWPOA/ZW
M+6LHOY079?$CU8G.&8L2@@,%1!#KV9(K# A*B#YH"T,AF&)$# :I3VB:7KG6
M;G2#C;YMA]Q1KJ&M<7P1G'JB@W^'3MAO;D0+W!%XXM[7;V^[Z>U9/Q+8BV)9
MT>P_Z6T]F@FFC_P$Y$ H$0$44 5H)"2(0APQ\Y:<1)9OQ'7)3 SK2MO3XD[#
M;&>A+$%UMC\.TZ'.W2'M-#8>T7;8GP-HI[6=>':O'@GGF;[YI;PJ[O,Y090D
M$6: $,0!HD%HOMXF!C%$)!"ZBTK?\CV%+8V)L33"IH48:4<F&_6Q!-+-]3@:
M!QEV1W';TG@.&S%_#H3;IG82V+%T)'[K7^=I+N$\9J&,&>$ JR !"(8:0*S[
M8X@1A8+&?D#< &RJ3(S@^H9GM+TON6MK;-7)$D17]^-0'&S<'<<N8^.!;$7]
M.4AV&=L)9>=B]XMHK_13YPE7>C*-!6")^:8W%4M J-(_<(B@BBD- ^MK9TW@
M(\/W="6IT;*_3K:VOA\N5T-V/ WSXG0I;#/Q45? UH$FO_"UF7[7]:ZMQQV^
M9,"@54I:'X1$)*(HD1Q$OM @$/-99S]$((1*2!'$0OJ#W[AK!CXR"/4<9+0L
M#\=:WO>3X.K(CH2!9NR^7*$C<[?O5F@&FNZK%3K2;WVS0M?CNU!H5E1WD>^G
MKS;WI*MOJSQ]]7]02P,$%     @ G3;W6BJ--5ND!@  RS   !0   !A;FDM
M,C R-3 W,C-?<')E+GAM;-6:6V_<MA+'W_,I]FQ?SWC%BT32B%WXN,F!<=S&
M2%RTZ,N"EZ%7J%8RN')L?_LSDKU)7-NM8"U@Y64O7%(S_,]/0W)6;W^\65>S
MSY@V95,?S-E>-I]A[9M0UA<'\U_/WX.>_WCXYLW;?P'\_I^/I[.?&G^UQKJ=
M'2>T+8;9==FN9NT*9[\UZ<_RLYV=5;:-35H#'/;#CIO+VU1>K-H9SWB^[;;]
M->VK(((L/ +/A0#II0?MI *ET1L>@I3&_/MBORA,8!G7(/+"@$1NP!FMP4;.
MBCS+<RVS_J)56?^YW[TXN\$93:_>]%\/YJNVO=Q?+*ZOK_=N7*KVFG2QX%DF
M%MO>\_ON-X_Z7XN^-S/&+/I?OW3=E$]UI,NRQ>\_GW[R*UQ;*.M-:VO?&=B4
M^YN^\;3QMNU5_T>_9L_VZ+[!MAMT3< X"+9WLPGSPS>SV9T<J:GP(\99]_[K
MQY,O)FU=[OEFO>C:%\<-<4 >]B/:VTL\F&_*]66%V[95PG@PIS'013)37'1F
M?K@;M_AJ[3+AAA#I9W=*#??#.R.#+>--BW7 NTEL+UPU_D&GJI.P^3*RL@ZK
MOG49L%SV5SURFS99WRZY-MZA+$!D1H/,M #KN00OA952"168?SC1SM,-N=HK
MOD&_=]%\7M"%%]WLNP^]#+T$C\S=R?$RO[>WV#GU7;)<!G+;@'4B!\GI%C%,
M.+#HN"X,BSG/1KG]K;6'7G\;QJ/D9TT*F"A';,W9Y!^$]#&=]ST6ES;1A<"O
MRBIL1\?4K'<1J[;9@7)W82%WYS.:=<24,)S>1>79R?4S:RES8M]S%Q$_PU0V
MX5T=?J+4NF369)[E%DS! TAG$%SA.*!P464N^J!V$_H'9@<QP*?/P,NU?&48
MWM5MV=Y^Q(NR4Z)N?[%K7,J<$;R>0_218 Z8@V4F0DY+HN)!VJ#-*!:>LCH(
M!3%=%$8K.0D23F@[EBZ;U O_B?3'X^:J;M/M<1-P::T(SD4!Y'TD;1P#8S,/
MJA"4WYA5W,<=@/&W3@SB1$Z=D]WI/ ELWI<5_G*U=IB6B 4+47-05EF0)BM
MTXX9-&6^W$A:)D.^ T:^6AP$1#YU(%ZHX"2B?VYO3@)I5<;R[I1Q/Q%KN3$Z
M("F"#J30$C32O*0JI/%*&29WD2Z>,3^(BV+J7.Q"VTE <A0"A6!S_T8G-61+
MS;1%J0T4N?!T&N>4YU26@7>65LC,!4J$.P#D"=.#X%!3AV.LIE,"XY@^?DCG
MS76]I!Q'J4XY,$B;:*GIQ7FK0 ?+/.J81RUWA\57PX.@T-\)%"_4<TI(]/NB
M#^DL-9_+VN,2B>;(=02C"T$+(QVWM149<*$R4UBI--_%>O*T]4%PF.\$CC'*
M3HF0LV;3VNJ/\O)NVZRLT[D4P)61M!*R JR2 7Q!_,<<C<9Q-8SG;0\K9F7?
M"1XOE_65X>B2WE%"V_LMC,YUX1DX4Y 4P3KRFT0)W+H0K?+:%:-P^-;:,  F
M7,Y\L72O'/+NGXWJ;-74V^-3#,XKR1C0(1E!N@+!REP!:1*DM)F4(VOO?[4X
M+/03KF*.DO"5P_\)_54B=!EWYV5;X5)A$)D7#+(\T/XW5W0PBH%#[DW,0TX+
MG!VW>?RKQ6'AGW#E<I2$KQS^\V2[?X\_W:Y=4RT+1!\*VME*SCK'@P7#"@\Q
MBX8+H62AU*C8/S W+/ 3+D6^7+R)W/3O;OS*UA?8U]II XN!10,AN@)DT>UF
M,Q% BZ@XG8FCP7%Y_RFKPQB8</5QM)2OC,)OY'R+]7&S7E_5]R6RS5*IS!M-
M>4L9RELRRQ!,4)86,/J>>8PLQU$L/&EV& P3+CF.%_.U$T-3E;YL*:G]3 ?<
M5-IJF5L=>4X*,.L,2&8]N"PX<-TF)RBGM!QW*'QL<Q@'$ZXNCI3QE2$X2]@1
MC+7'_OF,[M&>]"&2'TM5,"Z9D\ -<]VYAG):+$S_+!-GPBMK]"@8GK<]#(H)
M5Q=W).NTX#C9;*XP?3N77!#I3!60<\QH[3,%."84.*=SIY2SG(W+%__DP3!0
M)EQIW*G$DZ@VOEMCNJ!L^-_47+<KFMREK6^7)E@> \M N"R"E)D#[:. 0@GO
M'8D4;1A%RM\8'_;@U.3KC>.%G00?QR19LM4)(7[S/[Q=<L\+;6D"UA#ETJ #
MDZ.'3#(Z2.N<<3;N'/JDV6%,3+@$.5[,5Z;AB/)=Z'+>^\I>+*/1D62(@+;[
MVXUE- 5+FV<7D.LLYRS/W2@*'I@;%OT)5R%?+M[.HOYV\4B\4VHX?'/_0_?2
M/?M^^.;_4$L#!!0    ( )TV]UJ-&LS41"(  #:>   8    86YI<"TR,#(U
M,#<R,WAE>'@Y.3$N:'1M[3UK<]LXDM_O5^"22M:NDC22_(@?F:G2V,ZL]Q+'
M:SN3VD]7$ F)&%,$AR"M:'[]]0,@04EVG.PD]LYY/NPZ% DT&OWN1N-U4L[2
MGUXG2L8__=?K_^YVQ;&)JIG*2A$52I8J%I75V51\C)6]%MVN>^O(Y(M"3Y-2
M#/O#'?'1%-?Z1O+OI2Y3]9,?Y_4/_._7/] DK\<F7OST.M8W0L<_/M.#\<ZN
MW-\;;$UV]K?'_?WQJ]VM:*>_.Y2#X<[^5O]_MUX]@V_A??[(EHM4_?ALIK-N
MHA" @U?#O#R<Z[A,#@;]_HMGK?=*]:GLRE1/LP,"%WZ=&%B<^SDRJ2D.GO?I
MOT/\I3N1,YTN#OXV*K1,_]:Q,K-=JPH]X9^M_D,=#'!*^N?<P0!?ISI3'J;!
M$ $Y^93HL2[%_GYO\/H'?-^O9'4]LIC"DDJ3T^  IIY-A4S+'Y_)@>S]ED^?
M"5M$X;_X0S]A?YA_.G2CC$U9FMG!#@!YHXI21S)U."!T\,\.94/\,,0P(PCV
MJ?BI#7/]VS='WF (R'OS_D*<OGMW<GPZNCH1%R=O3T:7)[= M![:-300 4&J
MXGL1 :UC='8JSA-9S&2D*MH+*T999JHL4E9<*%NEI163PLS$V<E'<3SZESB"
M4?!%<873"S,1IV\__'IZ<O;R^>#5]J&8F$)\L$KH3)S+4L.:K)CK,A''6HX5
MS"'>R:A*92%.8C638N/XW<FF>)RXHW$.= ES1"UL;J_%)F-$W<BT(N&45;.Q
M*A!%MLKS5*'$@1=T]IN*2FTR*S*E8G@1<58F2I0HU4B^P3> %_HA]U@TF4>U
M ,ZQE:5OY"35,$ND\E+ 1OXE$'E95O%"G&2%25- SY5'2_=,OGP^W-H'R=$1
M@)I1.C.V%.'3)9I[]TBY\@L1XCDQ+Y1%>&(Q7HAW.DJD2L6H)RY!"ZJB(][U
MCGO(>1*H)E=%UV1=9+(L]E]*I#LA2R*=T0S@BV0F+DVD5;E JKL %LVDN,Q5
M!.O0%B;=&%U>7&ZB7*B >B\CQ*^>(",K?'GZE\#PD<DFJE @]P0(MU38*%%Q
ME7KF-+%<(-KV7C[?V3O<Z@LY$R=77[3R[RG7SR].SXY.KMZ?=<19[Q^]COA'
ME2[$<*O#%M'&+V_?_WR"(OWRX^G%R::']5L N![=HBO6Z)Z..,VB'A <_.1$
MXI&9Y3);;(J-,VEC^3OA'[\]W_2[XO15+(I07^''7F=%7F>5ZW76QB2M@ 4R
M6'(&$C52I<ETC#JL+.2-1K$,8GN6IS(K-SNBWQOL"[" -MPHFT0C%2N]O"6
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M8'"12JMZI!U%\;&>SE*)R2U1PHX8P_:#O?M'-9-C(C#8"B^>''(&0^_?L6&
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M_X!G_^#_DG*6_O1_4$L! A0#%     @ G3;W6OX1P0\U$0  FGH  !
M         ( !     &%N:2TR,#(U,#<R,RYH=&U02P$"% ,4    " "=-O=:
M^%7\?UP"  #;!@  $               @ %C$0  86YI+3(P,C4P-S(S+GAS
M9%!+ 0(4 Q0    ( )TV]UHH>*.%^PD  'U4   4              "  >T3
M  !A;FDM,C R-3 W,C-?;&%B+GAM;%!+ 0(4 Q0    ( )TV]UHJC35;I 8
M ,LP   4              "  1H>  !A;FDM,C R-3 W,C-?<')E+GAM;%!+
M 0(4 Q0    ( )TV]UJ-&LS41"(  #:>   8              "  ? D  !A
M;FEP+3(P,C4P-S(S>&5X>#DY,2YH=&U02P4&      4 !0!& 0  :D<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ani-20250723_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ani-20250723.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2025-07-23</startDate>
            <endDate>2025-07-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001023024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-07-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ANI PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-31812</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">58-2301143</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">210 Main Street West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Baudette</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">56623</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">218</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">634-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">ANIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
